We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Simple Blood Test Assesses Colon Cancer Risk

By LabMedica International staff writers
Posted on 06 Nov 2012
A novel blood test will help enable the physician to monitor the patient's colorectal cancer (CRC) risk over the course of their screening lifetime, especially for those who are aged 50 years or more. More...


The blood test does not require any advance preparation, only the collection of a small blood sample, and differs from other tests that often require fasting and other dietary restrictions and with those patients having to collect multiple fecal samples over the course of three days or more.

The test, known as the COLOGIC test, is based on the discovery that approximately nine out of ten patients with colorectal cancer are deficient in novel anticancer and anti-inflammatory metabolites in their blood. COLOGIC detects this deficiency to determine patient risk. The COLOGIC test has a sensitivity of 86% versus an average range of 35% to 61% for fecal occult blood test/fecal immunochemical test (FOBT/FIT). The specificity of the test is reportedly 90%.

Clinical support for COLOGIC includes four published papers outlining the science and clinical outcomes of a study involving 4,923 patients. The test measures levels of gastrointestinal tract acid-446 (GTA-446), a long-chain polyunsaturated fatty acid present in the serum. The CRC incidence rate in subjects undergoing colonoscopy with low GTA-446 levels was over six times higher than for subjects with normal GTA-446 levels and twice that of subjects with gastrointestinal symptoms.

The COLOGIC test was developed by Phenomenome Discoveries Inc., (Saskatoon, SK, Canada) and will provide an easily understood result on whether the individual has an elevated risk for colon cancer. Mario Castelli MD, a gastroenterologist, said, “Colorectal cancer is a completely preventable disease if we screen for it, and it gets more common as we get older, so that's why the recommendation is, usually starting at the age of 50, that everyone should be screened. This is a much simpler test. The patient just goes to the laboratory without any preparation, have a blood sample drawn and the results go to your physician within days.” It should be noted that COLOGIC test is not a substitute to colonoscopy. A positive test result should be followed up with a colonoscopy to confirm the presence of cancer.

Related Links:

Phenomenome Discoveries Inc.



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
All-in-One Molecular System
AIO M160
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image Credit: iStock

AI Tissue Analysis May Help Identify Missed Precancerous Colon Polyps

Colorectal cancer is diagnosed in an estimated 1.9 million people worldwide each year, often without symptoms in its early stages. Timely detection of precancerous lesions is therefore important, yet some... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: Beginning in 2027, Quest will provide access to the Onclarity Self-Collection Kit through clinician, health plan, and consumer-initiated testing channels, along with its patient service center network.

Collaboration to Expand Cervical Cancer Screening Access With At-Home HPV Collection

Cervical cancer is largely preventable with regular screening and early detection of human papillomavirus (HPV), the leading cause of the disease. Screening gaps persist, in part because traditional sample... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.